440 related articles for article (PubMed ID: 7141736)
1. Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells.
Livingston PO; Watanabe T; Shiku H; Houghton AN; Albino A; Takahashi T; Resnick LA; Michitsch R; Pinsky CM; Oettgen HF; Old LJ
Int J Cancer; 1982 Oct; 30(4):413-22. PubMed ID: 7141736
[TBL] [Abstract][Full Text] [Related]
2. [Serological analysis of melanoma patients receiving autologous melanoma cell vaccines].
Watanabe T
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt):261-72. PubMed ID: 6881976
[TBL] [Abstract][Full Text] [Related]
3. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines.
Livingston PO; Kaelin K; Pinsky CM; Oettgen HF; Old LJ
Cancer; 1985 Nov; 56(9):2194-200. PubMed ID: 4052966
[TBL] [Abstract][Full Text] [Related]
4. Serological survey of normal humans for natural antibody to cell surface antigens of melanoma.
Houghton AN; Taormina MC; Ikeda H; Watanabe T; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1980 Jul; 77(7):4260-4. PubMed ID: 6933476
[TBL] [Abstract][Full Text] [Related]
5. Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells.
Livingston PO; Albino AP; Chung TJ; Real FX; Houghton AN; Oettgen HF; Old LJ
Cancer; 1985 Feb; 55(4):713-20. PubMed ID: 2981601
[TBL] [Abstract][Full Text] [Related]
6. [Vaccine therapy of malignant melanoma. II. Serological evaluation of the immune responses to the injection using allogeneic melanoma cell vaccine].
Takeyama H; Watanabe T; Livingston PO
Gan To Kagaku Ryoho; 1983 Jul; 10(7):1624-33. PubMed ID: 6870307
[TBL] [Abstract][Full Text] [Related]
7. Serological analysis of cell surface antigens of malignant human brain tumors.
Pfreundschuh M; Shiku H; Takahashi T; Ueda R; Ransohoff J; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1978 Oct; 75(10):5122-6. PubMed ID: 283420
[TBL] [Abstract][Full Text] [Related]
8. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells.
Livingston PO; Takeyama H; Pollack MS; Houghton AN; Albino A; Pinsky CM; Oettgen HF; Old LJ
Int J Cancer; 1983 May; 31(5):567-75. PubMed ID: 6852975
[TBL] [Abstract][Full Text] [Related]
9. Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody.
Real FX; Mattes MJ; Houghton AN; Oettgen HF; Lloyd KO; Old LJ
J Exp Med; 1984 Oct; 160(4):1219-33. PubMed ID: 6237165
[TBL] [Abstract][Full Text] [Related]
10. Cell surface antigens of human renal cancer defined by autologous typing.
Ueda R; Shiku H; Pfreundschuh M; Takahashi T; Li LT; Whitmore WF; Oettgen HF; Old LJ
J Exp Med; 1979 Sep; 150(3):564-79. PubMed ID: 479762
[TBL] [Abstract][Full Text] [Related]
11. Common human melanoma membrane antigens detected by mixed hemadsorption microassay with serum from a patient undergoing immunotherapy with autologous tumor cells.
Liao SK; Leong SP; Sutherland CM; Dent PB; Kwong PC; Krementz ET
Cancer Res; 1978 Dec; 38(12):4395-400. PubMed ID: 82477
[No Abstract] [Full Text] [Related]
12. Allogeneic human liposomal melanoma vaccine with or without IL-2 in metastatic melanoma patients: clinical and immunobiological effects.
Adler A; Schachter J; Barenholz Y; Bar LK; Klein T; Korytnaya R; Sulkes A; Michowiz R; Cohen Y; Kedar I
Cancer Biother; 1995; 10(4):293-306. PubMed ID: 8590895
[TBL] [Abstract][Full Text] [Related]
13. Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.
Carey TE; Takahashi T; Resnick LA; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1976 Sep; 73(9):3278-82. PubMed ID: 1067619
[TBL] [Abstract][Full Text] [Related]
14. Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens.
Shiku H; Takahashi T; Oettgen HF
J Exp Med; 1976 Oct; 144(4):873-81. PubMed ID: 978138
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific antigens.
Pfreundschuh M; Shiku H; Takahashi T; Ueda R; Ransohoff J; Oettgen HF; Old LJ
Recent Results Cancer Res; 1980; 75():1-9. PubMed ID: 7232821
[TBL] [Abstract][Full Text] [Related]
16. Update on active specific immunotherapy with melanoma vaccines.
Conforti AM; Ollila DW; Kelley MC; Gammon G; Morton DL
J Surg Oncol; 1997 Sep; 66(1):55-64. PubMed ID: 9290695
[TBL] [Abstract][Full Text] [Related]
17. Immunofluorescent detection of common melanoma membrane antigens by sera of melanoma patients immunized against autologous or allogeneic cultured melanoma cells.
Leong SP; Sutherland CM; Krementz ET
Cancer Res; 1977 Nov; 37(11):4035-42. PubMed ID: 332343
[No Abstract] [Full Text] [Related]
18. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.
Weide B; Pascolo S; Scheel B; Derhovanessian E; Pflugfelder A; Eigentler TK; Pawelec G; Hoerr I; Rammensee HG; Garbe C
J Immunother; 2009 Jun; 32(5):498-507. PubMed ID: 19609242
[TBL] [Abstract][Full Text] [Related]
19. Serological detection of common human melanoma membrane antigens by microcomplement fixation and immunofluorescence.
Leong SP; Cooperband SR; Deckers PJ; Sutherland CM; Fried RM; Krementz ET
Oncology; 1983; 40(2):95-101. PubMed ID: 6338430
[TBL] [Abstract][Full Text] [Related]
20. Autologous antibodies to meningioma cell surface antigens.
Pfreundschuh M; Röhrich M; Piotrowksi W; Penzholz H; Fischer H
Anticancer Res; 1981; 1(6):367-72. PubMed ID: 6284017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
